Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. Issue 9 (25th August 2020)

• Record Type: Journal Article
• Authors: Yeh, Hsin‐Chieh; Bantle, John P.; Cassidy‐Begay, Maria; Blackburn, George; Bray, George A.; Byers, Tim; Clark, Jeanne M.; Coday, Mace; Egan, Caitlin; Espeland, Mark A.; Foreyt, John P.; Garcia, Katelyn; Goldman, Valerie; Gregg, Edward W.; Hazuda, Helen P.; Hesson, Louise; Hill, James O.; Horton, Edward S.; Jakicic, John M.; Jeffery, Robert W.; Johnson, Karen C.; Kahn, Steven E.; Knowler, William C.; Korytkowski, Mary; Kure, Anne; Lewis, Cora E.; Mantzoros, Christos; Meacham, Maria; Montez, Maria G.; Nathan, David M.; Pajewski, Nicholas; Patricio, Jennifer; Peters, Anne; Xavier Pi‐Sunyer, F.; Pownall, Henry; Ryan, Donna H.; Safford, Monika; Sedjo, Rebecca L.; Steinburg, Helmut; Vitolins, Mara; Wadden, Thomas A.; Wagenknecht, Lynne E.; Wing, Rena R.; Wolff, Antonio C.; Wyatt, Holly; Yanovski, Susan Z.;
• Is Part Of: Obesity. Volume 28:Issue 9(2020)
• Page Start: 1678
• Page End: 1686
• Publication Date: 2020-08-25
• Subjects: Obesity -- Periodicals; 616.398005
• DOI: 10.1002/oby.22936
• Languages: English
• ISSNs: 1930-7381

Abstract

Abstract : Objective: This study was designed to determine whether intensive lifestyle intervention (ILI) aimed at weight loss lowers cancer incidence and mortality. Methods: Data from the Look AHEAD trial were examined to investigate whether participants randomized to ILI designed for weight loss would have reduced overall cancer incidence, obesity‐related cancer incidence, and cancer mortality, as compared with the diabetes support and education (DSE) comparison group. This analysis included 4, 859 participants without a cancer diagnosis at baseline except for nonmelanoma skin cancer. Results: After a median follow‐up of 11 years, 684 participants (332 in ILI and 352 in DSE) were diagnosed with cancer. The incidence rates of obesity‐related cancers were 6.1 and 7.3 per 1, 000 person‐years in ILI and DSE, respectively, with a hazard ratio (HR) of 0.84 (95% CI: 0.68‐1.04). There was no significant difference between the two groups in total cancer incidence (HR, 0.93; 95% CI: 0.80‐1.08), incidence of nonobesity‐related cancers (HR, 1.02; 95% CI: 0.83‐1.27), or total cancer mortality (HR, 0.92; 95% CI: 0.68‐1.25). Conclusions: An ILI aimed at weight loss lowered incidence of obesity‐related cancers by 16% in adults with overweight or obesity and type 2 diabetes. The study sample size likely lacked power to determine effect sizes of this magnitude and smaller.